Ortho resubmits Duobrii in the US
Bausch Health group Ortho Dermatologics has resubmitted an application to market its plaque psoriasis lotion Duobrii in the US
Read More
Tag: Valeant
US regulators reject Valeant’s Duobrii
The US Food and Drug Administration has rejected Valeant group Ortho Dermatologics’ plaque psoriasis therapy Duobrii.
Read More
EU approves LEO Pharma’s psoriasis biologic
A new treatment option has been approved in the European Union for patients with psoriasis, paving the way for access to a novel approach for those with moderate-to-severe forms of the disease who are candidates for systemic therapy.
Read More
FDA nod for Valeant’s psoriasis drug
The US Food and Drug Administration has issued a green light for Valeant to market Siliq as a treatment for adults with moderate-to-severe plaque psoriasis, but with a boxed warning on suicide and a restricted prescriber programme.
Read More
FDA advisors back brodalumab with suicide risk plan
Valeant’s skin jab brodalumab has taken a big step towards US approval after regulatory advisors backed the drug for adult patients with moderate-to-severe plaque psoriasis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
